From our previous clinical trials, intracoronary infusion of granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells ( mob PBMCs) proved to be effective in improving myocardial contractility and reducing infarct volume in acute myocardial infarction. We tested the effect of priming mob PBMCs with erythropoietin (EPO) to augment its therapeutic efficacy.
Introduction
Stem-cell therapy in ischaemic diseases, such as myocardial infarction (MI) has been regarded as a new method to repair ischaemic tissue and promote neovascularization. Since the first in-human clinical trial using autologous bone marrow stem cells, 1 numerous clinical trials of cell therapy have been carried out with various results. Recent several reports of meta-analysis 2 -4 demonstrated the promising results that stem-cell therapy improves cardiac function and reduces infarct after acute MI. 5 Despite the proven efficacy of stem-cell therapy, there is still limitation in the therapeutic efficacy of current stem-cell therapy for patients with ischaemic heart disease. As a source of stem cells for clinical trials, we have used mobilized peripheral blood mononuclear cells ( mob PBMCs) that are enriched through † These authors contributed equally to this work.
mobilization of bone marrow cells by granulocyte colony-stimulating factor (G-CSF) and apheresis process in MAGIC-CELL trials. 6 The proportion of angiogenic progenitors was significantly increased and became comparable to bone marrow mononuclear cells. 7 We have demonstrated that intracoronary infusion of the mob PBMCs was effective in improving myocardial contractility and reducing infarct volume in patients with acute MI. Furthermore, it improved long-term clinical outcomes. 8 The promising effect of mob PBMCs may be due to the positive interaction in between various cells, and the minimal need of manipulation which is vulnerable to cell contamination. However, the therapeutic efficacy was limited mainly due to the poor retention rate after intracoronary infusion of the cells and the insufficient regenerative potency of the adult progenitors like mob PBMCs. 9, 10 As a practical breakthrough,
we thought that priming of the mob PBMCs before infusion would be a feasible and reasonable strategy and that erythropoietin (EPO) would be a good candidate as a priming agent. EPO, an erythropoietic growth factor that promotes survival, proliferation, and differentiation of erythroid progenitor cells, 11 has long been used for cell-based therapy in ischaemic diseases. The EPO receptor (EPOR) is a 59 kDa peptide found not only in erythroid cells, but also in endothelial cells 12 and mononuclear blood cells. 13 Along with its erythropoietic effect, EPO is known to have various ischaemiaprotective properties while the mechanisms were not yet fully elucidated. 14 Previous studies have shown that EPO increased endothelial cell proliferation and neovascularization, 15 induces the proliferation, differentiation, and adhesion of progenitor cells, 16 and has anti-apoptotic effects. 17 Thus in this study, we checked the presence of EPOR on mob PBMCs and evaluated the effect of EPO-priming on mob PBMCs in terms of vasculogenic properties in vitro and in vivo.
Methods
Expanded methods are available in the Supplementary material online, Appendix.
Peripheral blood stem cells enriched by G-CSF mobilization ( mob

PBMCs) and EPO-priming
Peripheral blood (200 mL) was obtained from seven normal volunteers and three elderly patients with informed consent according to the Declaration of Helsinki and was approved by the Institutional Review Board of the Seoul National University Hospital. The normal volunteers underwent daily subcutaneous injections of G-CSF (Dong-A Pharmaceutical, Seoul, Korea) at 10 mg/kg body weight for 3 days. The elderly patients were those who visited our institute for treatment of coronary artery disease. Immediately after the blood was obtained, mononuclear cells were fractionated from other components of peripheral blood by centrifugation on Ficoll-Plaque (GE Healthcare) gradient. Mononuclear cells were immediately used for experiments with or without EPO-priming for 6 h. In experiments to test the cytokine release by EPO-primed cells, EPO-primed mob PBMCs were cultured for 36 h and the supernatant was used to evaluate secreted cytokines.
EPO-priming consisted of a 6 h incubation with human recombinant EPO (Espogen prefilled injectionw, 10 000 IU/mL, LG Life Science) diluted in phosphate buffered saline (PBS), at a concentration of 10 IU/mL. A portion of mob PBMCs were used for analysis immediately after EPOpriming and others were washed and cultured in EGM2 MV (Lonza). After 36 h of cell culture, the supernatant was acquired by removing cellular debris via centrifuging. The concentration of secreted cytokines/chemokines was determined by using the Bio-Plex Prot TM Array System (kits and equipment of Bio-Rad, USA based on Luminex xMAP technology) in the case of TNF-a, IL-8, IL-10, PDGF-BB, VEGF, and basic FGF. To block the EPO pathway, EPO Rc blocking antibody (Santa Cruz), JAK inhibitor (AG490, Sigma), and AKT inhibitor (LY294002, Sigma) were used. Also for inhibiting integrin in the adhesion assay, integrin b1 and integrin b2 neutralizing antibodies (Santa Cruz) were used. For histological evaluation of arterioles, anti-a-smooth muscle actin (SMA, Sigma) antibody was used, and to evaluate the incorporated human cells in the ischaemic muscles, the samples were co-stained with anti-human CD34 antibody (DAKO) followed by incubation with FITC-conjugated secondary antibodies with Cy3-conjugated anti-mouse SMA antibodies.
In vivo
Myocardial infarction models of nude mouse
The mice were anaesthetized with 50 mg/kg intraperitoneal pentobarbital and then fixed in the supine position under anaesthesia as earlier. Then, the skin was dissected by a lateral 1.0 cm cut along the left side of the sternum, and the main trunk of the left coronary artery was ligated. Immediately after ligation, 2 × 10 5 cells from the respective groups in 30 mL serumfree EBM medium, or PBS were injected into the apex of the mouse. Mice were sacrificed by cervical dislocation and harvest was done 2 weeks after surgery.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Results are expressed as the mean + standard error of the mean. Comparisons between groups were performed using analysis of variance, with post hoc testing performed with Bonferroni analysis or unpaired t-tests, as appropriate. Values of P , 0.05 were considered statistically significant.
Results
EPO-priming induced the angiogenic factors and integrins on EPOR(1) mob PBMCs
The volunteer demographics and the complete blood count before and after G-CSF injection are shown in Supplementary material online, Table S1 . The effect of G-CSF mobilization was proved by the Complete Blood Count, which was done immediately before peripheral blood collection. G-CSF injection significantly increased the number of total leucocytes, segmented neutrophils, and monocytes (see Supplementary material online, Table S2 ). After Ficoll-plaque separation of mob PBMCs, we checked the cell population by Wright-Giemsa staining (see Supplementary material online, Figure S1 ). We analysed the effect of EPOpriming on mob PBMCs in two experimental steps; with or without FACS sorting by EPOR (see Supplementary material online, Figure S2 ). EPOR was expressed on 41.2 + 12.3% of mob PBMCs. We sorted the cells by the presence of EPORs, into EPOR(+) mob PBMCs and EPOR (2) mob PBMCs. The purity of the sorted cells was confirmed by FACS ( Figure 1A ) and immunofluorescence staining ( Figure 1B ). Before and after EPO-priming of the FACS sorted cells, we screened the mRNA level of several cytokines. The expression of genes before EPOpriming, varied according to the presence of EPOR. The expression of several genes such as IL8, TNFa, and MMP9 was higher in EPOR(+) cells than in EPOR(2) ones even before priming. However, after EPOpriming, the gene expression difference was significantly augmented. EPO-priming induced specifically EPOR(+) cells to markedly express IL8, IL10, bFGF, PDGF, MMP2, integrin aV, b1, b2, and b8, which is assumed as the effect of EPO-priming ( Figure 1C ). Considering that IL-8, IL-10, bFGF, and TNFa are well-known cytokines having vasculogenic potentials and that MMP9 and integrins are essential in vasculogenic cell recruitment, we focused on the vasculogenic effect of ex vivo EPO-priming.
The effect of EPO-priming in the whole mob PBMCs and its signalling pathway
In the future clinical application, FACS sorting of mob PBMCs by EPOR would be a certain burden in terms of practicability of the protocol. Moreover, mob PBMCs are currently used cells for stem-cell therapy and have proved to be effective in our prior trials. 8 -10 Thus, using the whole cell group (without EPOR sorting), we assessed the effect of EPOpriming. EPO-priming of whole mob PBMCs also significantly induced the expression of IL8, IL10, basic FGF, MMP9, Integrin aV, and b8 compared with veh-priming ( Figure 2A ). Although the significant increase in some molecules disappeared in the whole cell group (i.e. PDGF, integrin b1, b2), EPO-priming was still proved to increase the expression of vasculogenic molecules in whole mob PBMCs that are used in MAGIC-CELL clinical trial. 8 We then evaluated the surface molecules of EPO-primed mob PBMCs ( Figure 2B ). The integrin expression profile was altered by EPO-priming. The expression of integrin b1, b2 increased in EPOprimed mob PBMCs, whereas integrin a4 and a5 were similar to the vehprimed mob PBMCs. This was concordant with the quantitative real time PCR results of EPOR(+) mob PBMCs.
Regarding cell viability, EPO-priming reduced the number of apoptotic cells double-positive for PI and Annexin V. Regarding cell subpopulations, EPO-priming significantly increased CD14(+) monocytes resulting in the reduced proportion of CD66(+) neutrophils. Among the monocyte population, we observed a polarization shift like induction of highly vasculogenic CD14(++)/CD16(+) cells.
To confirm the signalling pathway down to EPOR, we performed western blot analysis for total and phosphorylated JAK2 and Akt protein. After 5 min of EPO-priming, these signalling molecules are phosphorylated and activated, which was blocked by the EPOR antibody ( Figure 3A) . Next, we examined the effect of JAK or Akt inhibitor on the release of pro-angiogenic growth factors from these cells. EPO-priming significantly increased mRNA expression of IL8, IL10, bFGF, and PDGF, which was effectively prevented by EPOR blocking antibody, JAK inhibitor, or Akt inhibitor ( Figure 3B) . ELISA of supernatant from mob PBMCs demonstrated that secretion of these factors was remarkably induced by EPO-priming, which was obliterated by EPOR blocking antibody, JAK inhibitor, or Akt inhibitor. ELISA results were corrected by the viable cell count after priming agent without/with blockers ( Figure 3C , Supplementary material online, Figure S3 ).
Two faceted effects of EPO-priming on mob
PBMCs: paracrine action and adhesion on endothelial cells mob PBMCs can directly take part in angiogenesis, whereas the paracrine effect may also be important. Especially, monocytes are known to differentiate into various cells and secrete cytokines which are provasculogenic. 18 We analysed the culture supernatant of EPO-primed EPO-priming increased mob PBMCs adhesion to both fibronectin and HUVECs, which were reduced by EPOR blocking antibodies, integrin b1 and b2 neutralizing antibodies ( Figure 5A-C) . The increased adhesion could have originated from the improved survival by EPO-priming. However, integrin neutralizing antibodies had no effect on cell viability but reduced adhesion, whereas EPOR blocking antibody pre-treatment reduced viability along with adhesion ( Figure 5D and E). Therefore, we concluded that the improved adhesion is integrin-mediated.
3.4 EPO-primed mob PBMCs enhance neovascularization in ischaemic limb and repair myocardium after infarction through cellular and humoral mechanisms PBMCs on HUVECs and fibronectin, which were abolished by EPOR blocking antibody, integrin b1 and b2 neutralizing antibodies. (D) Cell viability was improved by EPO-priming and reduced by EPOR blocking antibody, whereas this was not influenced by integrin neutralizing antibodies. Therefore, increased adhesion was not due to increased viability, but was an integrin-mediated effect (n ¼ 3 for all results). measurement of the blood flow by the LDPI analyser on Day 0, 3, 7, 14, and 21, the blood flow recovery to the ischaemic hindlimb was significantly facilitated by EPO-primed mob PBMCs, compared with PBS or vehprimed mob PBMCs ( Figure 6A ). We confirmed that sufficient degree of ischaemia was induced in this model by histological examination of the ischaemic tissue with regenerating muscles at 21 days (see Supplementary material online, Figure S6 ). For quantification of angiogenesis, we counted the number and area of newly formed mature vessels in the ischaemic limb. EPO-primed mob PBMCs significantly increased the number and area of SMA(+) vessels ( Figure 6B) . Furthermore, we confirmed the direct incorporation of human mob PBMCs into mouse vessels through staining with human specific endothelial marker anti-CD34 antibody ( Figure 6C and Supplementary material online, Video S1 showed a significantly better therapeutic efficacy than veh-primed cell or PBS control in terms of infarct size and infarct wall thickness. Vehprimed cell was better than PBS control ( Figure 6D ). Furthermore, injection of EPO-primed mob PBMC resulted in the least amount of cardiac fibrosis compared with the other two treatments (see Supplementary material online, Figure S7 ). Next, to show the paracrine vasculogenic properties of mob PBMCs, we created mouse ischaemic hindlimb models and injected cell supernatant from primed mob PBMCs. As a result, injection of supernatant from EPO-primed mob PBMC showed a significantly better efficacy than the supernatant from veh-primed mob PBMC or PBS control in terms of blood flow recovery to ischaemic limb ( Figure 6E ), as well as neovascularization with mature vessels (see Supplementary material online, Figure S8 ).
EPO-priming of PBMCs from the elderly patients with coronary artery disease
Those who would benefit from EPO-priming are patients with myocardial infarction. Therefore, we performed EPO-priming of PBMCs from three elderly patients with coronary artery diseases. Patients were 66.7 + 5.0 years old and the clinical diagnosis was angiographically confirmed. EPO-priming significantly induced the expression of IL10, PDGF, MMP2, integrin a4, b1, b2, and b8, which was reduced by EPOR blocking antibody. Furthermore, EPO-priming induced M2 polarization, reduced apoptosis, and stimulated integrin surface expression, which was prevented by blocking antibody against EPOR. Such responses of PBMCs from elderly patients to EPO-priming were consistent with responses of mob PBMCs from healthy young volunteers (see Supplementary material online, Figure S9 ).
Discussion
Through this study, we have shown the beneficial effect of ex vivo EPOpriming to increase the vasculogenic potential of human mobilized peripheral blood stem cells after G-CSF administration. By EPO-priming, mob PBMCs increased the synthesis of cytokines and integrins that involve in vasculogenesis. Furthermore, EPO-priming changed the cell viability or phenotype of mob PBMCs by reducing apoptosis and inducing shift of monocyte polarity toward vasculogenic CD14(++)/CD16(+) mononuclear cells. In vivo models also demonstrated that injection of EPO-primed mob PBMCs achieved a greater vasculogenesis in the ischaemic tissue than that of veh-primed mob PBMCs did. These findings strongly suggest that ex vivo EPO-priming of mob PBMCs can be a feasible and effective method to augment the efficacy of cytokine-base peripheral blood stem-cell therapy for patients with MI.
New strategy to overcome the limited efficacy of adult stem-cell therapy
During the past decade, a vast body of researches has been done on stem-cell therapy for patients with MI and reported significant efficacy in improving contractility and reducing infarct scar. 2 -4 But the problem was the limited efficacy; improvement of left-ventricular ejection fraction just by 3% and reduction of infarct size just by 5 mL. Several methods to overcome such a limitation have been proposed, such as, increasing cell numbers, genetic manipulation of the adult progenitor cells, or adoption of potent stem cells rather than adult progenitor cells. Increasing cell numbers may not be feasible because of the technical limitation of intracoronary or trans-catheter endomyocardial injection. Genetic manipulation or adoption of more potent cells derived from embryonic stem cells may encounter the safety issue before clinical application. Under these situations, priming of the adult progenitor cells before implantation would be a very feasible and safe way to augment the therapeutic efficacy, which has been well demonstrated by our previous report. 20 In this previous paper, we found that most of mob PBMCs expressed Tie-2 receptor and that priming of mob PBMCs with angiopoietin-1 significantly enhanced the transdifferentiation of mob PBMCs to endothelial lineage by turning on Ets-1 factor and the expression of integrins on the surface of mob PBMCs, leading to significant improvement of retention efficiency and therapeutic efficacy of mob PBMCs after intra-arterial delivery. 20 But we encountered the unexpected difficulty to realize this concept in clinics because it is very difficult to make the potent angiopietin-1 as human-or clinical-grade to meet the economical criteria during mass production. This is the reason why we searched for another cell-primer that is feasible in clinical application and paid attention to EPO because it is currently used in clinics and has several beneficial effects on cardiovascular system in the situation of MI.
EPO as a priming agent
EPO, being a well-known cytokine controlling erythropoiesis, has been tried to patients with MI with disappointing results, probably because of the insufficient local concentration at the target infarcted myocardium or because of the unwanted systemic effects. 21, 22 With adoption of ex vivo cell priming strategy, we expect several benefits; to maximize the effects of EPO on target cells, i.e. enhanced proliferative, vasculogenic, and anti-apoptotic properties, while to avoid the systemic side effects of EPO. With this ex vivo cell-specific priming strategy, we could use the highest dose of 10 IU/mL, which is known to have maximal proliferative effect in prior studies. 16, 23 In a previous study, 24 EPO was once used as a priming agent for late endothelial progenitor cells (EPCs) that already have good vasculogenic potentials with high expression of VEGFR-2, CD31, and Tie2. and our strategy to prime these cells ex vivo requires just several hours' incubation without ex vivo cell culture. Furthermore, we also checked the effect of EPO-priming on whole population of mob PBMCs without EPOR sorting. In the practical point of view, ex vivo cell sorting or purification process by FACS would be a limiting step that may be associated with damage to cell viability, risk of contamination, deprivation of possible cell-to-cell synergistic interactions, or economic burden. That is the rationale for us to use whole mob PBMCs without sorting in MAGIC-CELL trials. 6, 8, 10, 25 We were able to reproduce the beneficial effect of EPO-priming also in the whole mob PBMCs population in terms of in vitro angiogenic gene expression as well as in vivo vasculogenic effect in the two different models, proving this strategy readily applicable in the clinic. The effect of EPOpriming could be classified into two levels; the paracrine effect to form a vasculogenic niche and the direct cell-modulating effect.
Specific effects of EPO priming through EPO-EPOR pathway
Paracrine action of EPO-primed mob PBMCs: formation of a vasculogenic niche
Secretion of cytokines such as IL8 and IL10 from EPO-primed mob PBMCs may be helpful to make the vasculogenic niche in the target ischaemic tissue when these cells delivered. IL8 is a well-known cytokine that enhance proliferation and survival of endothelial cells by activation of MMP2 and MMP9. 28, 29 IL10 is also a well-known vasculogenic cytokine that induces neovascularization and induce pro-vasculogenic phenotype of macrophages. 30 This paracrine effect was proved by functional analysis where culture supernatant of EPO-primed mob PBMCs exerted benefits to induce tube formation and cell migration of HUVECs. Also, in vivo models showed that cell supernatant of EPO-primed mob PBMCs improved perfusion in ischaemia, which can support the paracrine action. However, the increase in perfusion ratio at 3 weeks was less than that compared with the EPO-primed mob PBMCs group (36.9% in the supernatant injection group vs. 50.7% in the cell injection group), which can explain the direct role of cells itself.
Direct cell-modulation by EPO-priming
EPO-priming up-regulated integrin expression that is known to have an important role in vasculogenesis, including facilitation of wound healing. 5 Various combinations of integrins are known to enhance cell homing and angiogenesis. 5 Specifically, integrins aV, b1, b2, and b8 increased in gene expression by EPO-priming. Elevation of integrins b1 and b2 were confirmed at protein level also by FACS analysis. PBMCs was induction of shift in monocytes polarization towards CD14(++)/CD16(+) monocytes that are so called vasculogenic/anti-inflammatory monocytes expressing IL10 and that play a pivotal pro-healing action in debris scavenging, wound healing, and angiogenesis. 31 Furthermore, EPO-priming of mob PBMCs proved to be anti-apoptotic antiinflammatory, which was corroborated by reduction of Annexin V/PI double positive apoptotic cells as well as CD66(+) polymorphonuclear cells. Taken all together, EPO-priming could induce vasculogenesis by providing vasculogenic niche to target ischaemic tissue through paracrine action of mob PBMCs, by directly up-regulating the expression of integrins, and by inducing polarization of monocyte phenotype to vasculogenic monocytes.
Conclusion
Ex vivo EPO-priming augmented the vasculogenic potential of human 
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